{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:20:48Z","timestamp":1789809648252,"version":"4.0.1"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EJR"],"abstract":"<jats:p>Abstract\n\tObjective: The interleukin 17 (IL-17) cytokine family is involved in a number of chronic inflammatory diseases. In spite of contradictory findings and a lack of causality in clinical studies, IL-17 inhibition for systemic lupus erythematosus (SLE) has regained attention as a potential therapeutic pathway, after demonstrating disease-modifying capabilities in ankylosing spondylitis. We investigated the clinical associations of interleukin 17 A (IL-17A) in patients with SLE.\n\n\t\u00a0\n\n\tMaterial and Methods: A cross-sectional study was performed involving SLE patients (n=102; age: 49 years; 86% female) recruited from a regional registry. IL-17A levels were determined by immunoassay, disease activity by Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K), and cumulative damage by Systemic Lupus International Collaborative Clinics Damage Index (SDI) scores. Non-parametric techniques were used to examine the association between IL-17A and disease activity and autoantibody profiles were compared with healthy controls (n=31): principal component analysis (PCA) was used to determine the interplay of immune cells across disease states and damage development in SLE patients.\n\n\t\u00a0\n\n\tResults: SLE patients had higher IgG levels, lower T-cell and B-cell counts, but median IL-17A levels did not differ from the controls (28.4 vs. 28.4 pg\/mL, p=0.9). In SLE patients, IL-17A did not correlate with SLEDAI-2K or SDI, but was inversely related with age (correlation coefficients, Rs.=\u20130.29, p&lt;0.05), systolic blood pressure (Rs.=\u20130.31, p&lt;0.05), years of smoking (Rs.=\u20130.43, p&lt;0.05), cumulative heart (Rs.=\u20130.22, p&lt;0.05), and malignancy damage (Rs.=\u20130.18, p&lt;0.05). Serological correlations for IL-17A existed with immunoglobulin G (IgG) levels (Rs.=0.21, p&lt;0.05), high sensitivity C-reactive protein (hs-CRP) levels (Rs.=0.28, p&lt;0.05), proteinuria (Rs.=0.64, p&lt;0.05), and pre-albumin (Rs.=\u20130.22, p&lt;0.05). Longitudinal data showed only modest fluctuation in IL-17A levels, independent of SLEDAI-2K.\n\n\t\u00a0\n\n\tConclusion: These results suggest that IL-17A, while participating in inflammation, may also serve a protective purpose in SLE patients.\n\n\t\n<\/jats:p>","DOI":"10.5152\/eurjrheum.2017.16059","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T08:21:41Z","timestamp":1488356501000},"page":"29-35","source":"Crossref","is-referenced-by-count":28,"title":["IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role"],"prefix":"10.5152","volume":"4","author":[{"given":"Warren","family":"Raymond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro","family":"Ostli-Eilertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheynae","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Nossent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2019,9,3]]},"container-title":["European Journal of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/download\/153\/153","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:27:49Z","timestamp":1753774069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/view\/153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,9,3]]}},"URL":"https:\/\/doi.org\/10.5152\/eurjrheum.2017.16059","relation":{},"ISSN":["2148-4279"],"issn-type":[{"value":"2148-4279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}